ストックスクリーナーアプリを入手
3.36
1.82%
0.06
前日終値:
$3.30
開ける：
$3.1
24時間の取引高:
3,131
Relative Volume:
0.12
時価総額：
$4.55M
収益：
-
当期純損益:
$-8.22M
株価収益率:
-0.4513
EPS:
-7.4459
ネットキャッシュフロー:
$-4.78M
1週間 パフォーマンス:
-4.79%
1か月 パフォーマンス:
+9.45%
6か月 パフォーマンス:
-25.17%
1年 パフォーマンス:
-44.46%
1日の値動き範囲:
$3.10
$3.40
1週間の範囲:
$3.10
$3.56
52週間の値動き範囲:
$2.32
$7.2225
Synaptogenix Inc Stock (SNPX) Company Profile
名前
Synaptogenix Inc
セクター
電話
(973) 242-0005
住所
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
SNPX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNPX
Synaptogenix Inc
|
3.36 | 4.55M | 0 | -8.22M | -4.78M | -7.4459 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Synaptogenix Inc (SNPX) 最新ニュース
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - MSN
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Synaptogenix Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - Marketscreener.com
Synaptogenix (SNPX) Extends CEO’s Employment and Forms Special Committee to Explore Strategic Opportunities - Defense World
Synaptogenix forms committee to explore strategic opportunities - Investing.com
Synaptogenix forms committee to explore strategic opportunities By Investing.com - Investing.com South Africa
Synaptogenix Restructures Leadership Amid Strategic Refocus - TipRanks
Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan
Synaptogenix shareholders approve key proposals at annual meeting - Investing.com India
Synaptogenix shareholders approve key proposals at annual meeting By Investing.com - Investing.com Canada
Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN
Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR) - Defense World
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix appoints new auditor as Morison Cogen exits By Investing.com - Investing.com UK
Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com
Synaptogenix announces new preferred stock series - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com India
Synaptogenix secures $5 million in preferred stock financing - Investing.com India
Synaptogenix (NASDAQ:SNPX) Trading 2.6% Higher - Defense World
Synaptogenix extends preferred shares maturity date - Investing.com
Synaptogenix Inc (SNPX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews
SNPX (Synaptogenix) Earnings per Share (Diluted) : $-37.19 (TTM As of Mar. 2024) - GuruFocus.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 - InvestorPlace
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix - The Pharma Letter
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix’s PUFA analogues for spinal cord injury - BioWorld Online
New collab to probe potential of fatty acid analogs in Alzheimer's - The Pharma Letter
Synaptogenix begins pre-clinical trials for SCI treatment - Investing.com
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - StockTitan
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix increases psilocybin stake with PsygaBio - Green Market Report
Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Markets Insider
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider
Onconetix (NASDAQ:ONCO) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million. - Marketscreener.com
'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com
Advanced Alzheimer's: Bryostatin-1 may be safe, effective - Medical News Today
Bryostatin found to slow cognitive decline in advanced Alzheimer's... - Alzheimer's News Today
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.31% - Investing.com India
Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the MarketAzafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos Health - PR Newswire
Best Penny Stocks To Buy Now? 10 Under $1 To Watch - Penny Stocks
Synaptogenix Inc (SNPX) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):